Toxicity profile of lapatinib plus capecitabine in advanced breast cancer – a single-centre follow-up study
Journal Title: OncoReview - Year 2015, Vol 5, Issue 4
Abstract
Breast cancer is the most prevalent female neoplasm in Poland as well as in the rest of the world, accounting for 25% of all cancers. Lapatinib is a reversible inhibitor of the HE -1 and HER-2 tyrosine kinase receptors. Combined with capecitabine, it is administered in patients suffering from advanced breast cancer with HER-2 receptor overexpression.The present article analyses data obtained from medical records of 24 breast cancer patients treated with lapatinib and capecitabine in the years 2010–2015, in order to examine the treatment-related toxicity. The major adverse effects observed under treatment included diarrhoea, nausea, emesis, skin toxicity, and elevated transaminases. In 3 patients, grade 3 adverse events were reported, as assessed in accordance with CTCAE. The most frequent cause behind the cessation of treatment was disease progression. The analysis has indicated that lapatinib plus capecitabine is a well tolerated treatment regimen.
Authors and Affiliations
Zuzanna Borysiewicz, Iwona Ryniewicz-Zander
Keywords
Related Articles
- EP ID EP78729
- DOI 10.5604/20828691.1189750
- Views 205
- Downloads 0
Kontrolowane placebo, z podwójnie ślepą próbą, prospektywne, randomizowane badanie skuteczności oktreotudu LAR w kontroli guza u chorych na guzy neuroendokrynne środkowej części prajelita z przerzutami: raport grupy badawczej PROMID
Wstęp: Analogi somatostatyny są wskazane w opanowywaniu objawów u chorych na żołądkowo-jelitowo-trzustkowe guzy neuroendokrynne (NETs). Zdolność analogów somatostatyny do kontrolowania wzrostu wysoko zróżnicowanych NETs...
Dlaczego refundacja leku sierocego wymaga szczególnego podejścia?
Największym problemem dotyczącym refundacji produktów sierocych jest ich wysoka cena. Decyzje refundacyjne i cenowe w przypadku leków sierocych są szczególnie mocno powiązane. Jeśli dotyczą nowo wprowadzanych na rynek te...
Meeting the human
We often have to deal with problems which force us to making difficult choices and decisions that have not only clinical aspects but also ethical during the oncologist’s work. Unfortunately there is not enough place in a...
Planning hormonal therapy in prostate cancer patients – expert view
In last decades prostate cancer became one of the most common cancers in the World, and one of the most common cancer death diagnosis. As a hormone-dependent entity for almost 70 years prostate cancer is treated with hor...
Compliance, adherence, persistence – causes and consequences of non-adherence to medical recommendations
Patients’ non-adherence is among the most serious health problems of mankind. It was recognized as one of the major barriers to achieving benefits from therapies based on current medical knowledge. The aim of this paper...